🇺🇸 FDA
Patent

US 11085022

Inflammation-targeted neutrophil granulocyte drug delivery system and use thereof

granted A61KA61K31/192A61K31/337

Quick answer

US patent 11085022 (Inflammation-targeted neutrophil granulocyte drug delivery system and use thereof) held by CHINA PHARMACEUTICAL UNIVERSITY expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CHINA PHARMACEUTICAL UNIVERSITY
Grant date
Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/192, A61K31/337, A61K31/5383, A61K31/7105